1️⃣ FDA puts a real regulatory frame around genome editing
FDA issued draft guidance on April 14 setting NGS-based expectations for off-target and genome integrity assessment in human gene therapy products.
💡 Why it matters
This does not speed approvals by itself. It removes some ambiguity around what a credible safety package needs to look like before sponsors get into the clinic.
☕ Coffee talk
Which teams actually wanted clarity here, and which ones were still living off regulatory fog?
2️⃣ FDA is forcing trial disclosure back onto the agenda
The agency said on April 13 that it had contacted more than 2,200 sponsors and researchers tied to more than 3,000 trials with missing or incomplete ClinicalTrials.gov results.
💡 Why it matters
For investors, hidden negative data is not just a governance issue. It distorts diligence, stretches timelines and raises the odds of ugly surprises later in the file.
☕ Coffee talk
How many pipelines still look cleaner than they are because the bad studies never really made it into the room?
3️⃣ The IPO window is open again, but only for very obvious winners
Kailera priced a $625M IPO on April 16 and surged in its April 17 Nasdaq debut, while more biotechs are lining up behind it for the public market.
💡 Why it matters
This looks less like a broad reopening and more like a selective bid for late-stage, big-category stories. Good science still matters, but so does being easy to underwrite.
☕ Coffee talk
Is the window really back, or did obesity just get its own exemption from normal biotech rules?